FDG-PET scans in these patients allow clinicians to determine whether the tumors are still viable or not, thus playing a significant role in making treatment decisions.

A new study in JACC: Cardiovascular Imaging focuses on a potential new side effect of COVID-19, highlighting the continued importance of monitoring these patients going forward. 

The demand is especially great for asymptomatic individuals of all races and ethnicities.

In the study, patients who had recovered from an COVID infection were injected with a small amount of the 89Zr-labeled radiotracer before undergoing a uExplorer PET/CT scan.

Better risk stratification can improve clinical decision making and better outcomes, experts involved in the study explained in EJR.

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

A clinical trial pitting MRI against a burgeoning PET/CT technique has found the de facto defending champion better at revealing the presence of any grade of prostate cancer.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality.